Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT02216058

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Medfavour (Beijing) Medical Co., Ltd (from the registry)
Registry
  • NCT NCT02216058
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02216058. Allocation not applicable; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2017-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery Disease
Intervention (Device)
NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
Lead sponsor
Medfavour (Beijing) Medical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02216058
Content hash
d13b44f8b0761069f2e9206079d48107280611f45ca33d78d7b2c8dd9b0b0b1d